Abstract Ex vivo lung perfusion has been proposed as a method to identify good quality organs from the suboptimal donor pool, and as a method to reduce cold ischemic times by using a transportable system. As lung transplant centers adopt this new technology, encouraging reports are being published. In addition, single center experiences are now being validated by prospective and multicenter clinical trials. In the present report, we will summarize the rationale behind the use of ex vivo lung perfusion, the current different methodologies, and the published international experiences with its use.
Introduction
In the U.S., nearly 2,000 lung transplants are performed every year; however, many patients still die waiting for an organ [1] . More patients could be saved if more lungs met transplantation criteria.
Lung quality is the major limitation in the utilization of donated lungs [2] . The donor lung is subjected to significant physiological and biochemical stresses during brain death, often compounded by trauma, aspiration of gastric contents, and even embolization of trauma-fragmented brain tissue [3] . Tissue injury during this process results in a systemic innate inflammatory response that compromises the homeostasis of the alveolo-capillary membrane leading to poor oxygenation [4] . Improving organ quality while suppressing this deregulated response before transplantation is highly desirable. Ex vivo lung perfusion (EVLP) provides us with the opportunity to re-evaluate and recondition lungs before transplantation [5] .
The use of EVLP has generated great enthusiasm. Several centers around the world have presented encouraging results when using EVLP as a platform to screen organs from the substandard donor pool [6] [7] [8] [9] . In addition, data from these centers have demonstrated equivalent outcomes when transplanting standard criteria lungs or lungs selected using EVLP.
The goal of this review is to summarize the rationale, background, and the current published clinical experiences with the use of ex vivo lung perfusion.
Rationale for the Use of EVLP
In the last decade, more aggressive pharmacological management has led to an increase in the number of organs placed per donor. But still only up to 20 % of lungs offered are transplanted in most countries [10] . Cold ischemia, the current preferred method of lung preservation, reduces tissue metabolism limiting the opportunity for interventions after the lungs are explanted [11] .
Ex vivo normothermic (37°C) lung perfusion has been proven by our group and others as a reliable platform to screen lungs that had been previously rejected for transplant because of poor quality [12] [13] [14] [15] . The ongoing NOVEL Trial has demonstrated that about 60 % of the lungs evaluated improve their quality during EVLP [16 •• ].
This quality improvement seems to be related to the low stress conditions of EVLP allowing the lung cells to regain a more physiological status before transplantation [17 •• ] . Other favorable aspects of EVLP are the dehydration of the lung tissue by re-establishing Starling forces that may have been altered during brain death, and the re-expansion of atelectatic lung areas, which improve the ventilation/perfusion ratio leading to better gas exchange.
Clinical EVLP Methodologies
Contemporary clinical applications of EVLP could be summarized as: a method to increase the number of transplantable lungs by reconditioning unused/rejected lungs from the donor pool (Lund and Toronto's methods) [6, 9] , and a method to replace cold preservation by using a transportable lung perfusion system (Organ Care System method) [18 •• ] . Table 1 summarizes the differences and similarities between the steps followed by these methods during EVLP initiation and EVLP stable-reconditioning modes.
When following the Lund or Toronto method, lungs are procured in the standard fashion and transported cold to the recipient center where they are rewarmed for EVLP assessment. When following the OCS method, the lungs are procured in the standard fashion, cold flush, but immediately placed in the EVLP system for normothermic transport to the recipient center. Any of these methodologies requires a stepwise rewarming and an increase of flow in order to maintain pulmonary artery pressures under 15-20 mmHg. During the rewarming period, the vasculature is particularly fragile and elevated pressures can result in worsening edema by increased capillary filtration or by the irreversible loss of the alveolo-capillary barrier integrity [19] . Ventilation is started when the outflow reaches a temperature of 32°C. The ventilatory strategy is to maintain low airway pressures by using low tidal volumes, which, in combination with low vascular pressures, reduces the possibility of damaging the lungs by inducing stress failure [20] [21] [22] . A sweep gas flow is also initiated at 32°C. EVLP contains an oxygenator that works as a deoxygenator by using a sweep gas formulation of 7 % CO 2 ?93 % N 2 (Lund) or 8 % CO 2 ?6 % O 2 ?86 % N 2 (Toronto). The flow rate is titrated to maintain a pulmonary arterial PCO 2 of 34-38 (Lund) [9] or 35-45 mmHg (Toronto) [6] . Toronto recommends a 0.5-L/ min starting flow rate, and we have found that the final flow typically stabilizes at 2-4 L/min.
Once the outflow temperature reaches 37°C, the system can be considered stable and the lungs can be evaluated. When following the Lund or Toronto methodology, lungs are re-evaluated every hour until they meet acceptability criteria for transplantation. If the lungs do not meet quality criteria, the system is placed back into a reconditioning mode and the lungs are re-evaluated an hour later. Given the low pressures and tidal volumes, alveolar recruitment maneuvers may be necessary through the perfusion time to ensure an adequate ventilation/perfusion ratio.
When using the Organ Care System for transport, a PO 2 / FiO 2 ratio is normally obtained at the donor site when the lungs are stable in the system and a second PO 2 /FiO 2 ratio once in the recipient operating room before making the decision to transplant. Table 2 summarizes the evaluation mode and variables used to reassess lung quality during EVLP.
Clinical Experiences with EVLP
A review of www.clinicaltrials.gov revealed nine clinical trials studying the use of EVLP. Most of these trials are focused on the expansion of the usable lung donor pool, however one trial is looking at the effects of using a transportable EVLP system to replace cold ischemia as the standard of care. Table 3 shows the most relevant aspects of the clinical trials studying the use of EVLP.
Published literature, both in the form of abstracts and full reports, reveals that many centers are using different EVLP Lungs underwent a period of cold ischemia (i.e. time from harvest to start of EVLP and stop of EVLP to reperfusion after transplant), the mean cold ischemic time was 134 min for the first lung and 249 min for the second lung. The 30-day survival was 100 %, one patient died at day 140 after transplant from cardiomyopathy of unknown origin. In 2013, the INSPIRE trial investigators (NCT01630434), presented their interim results after 60 lung transplants at the International Society of Heart and Lung Transplantation Society meeting in Montreal [23] ; unfortunately, the published abstract does not provide information other than the number of lungs preserved using this methodology. Table 4 International clinical experience with EVLP as a method re-assess and or recondition lungs EVLP as a Method to Re-assess and or Recondition Organs from the Unused Lung Donor Pool
In 2001, Stig Steen [24] reported the first successful use of EVLP when a 54-year-old woman with COPD received a right lung from a 54-year-old donor who underwent cardiac arrest after myocardial infarction. Although initially the method was conceived to evaluate grafts from donors after cardiocirculatory arrest (DCD), Steen's group identified the potential of EVLP as a method to re-evaluate grafts originally rejected for transplantation based on their poor oxygenation. Subsequently in 2006, Wierup et al. [25] described their initial experience reconditioning six donors previously rejected by Scandiatransplant, Eurotransplant, and UK transplant organizations. After his report, several centers recognized the value of EVLP in identifying good quality lungs within the donor pool that were not accepted for transplantation. One of these groups was the University of Toronto that not only identified the potential of EVLP for re-assessing and reconditioning lungs but also as a platform to deliver therapies looking to improve outcomes after transplantation. To achieve this, the Toronto group developed a low stress perfusion/ventilation strategy in order to maintain lungs ex vivo at a physiological body temperature for long periods of time, i.e. 12 h. In 2011, the results from the first prospective clinical trial using EVLP, the HELP trial, conducted by the Toronto group were published [26
The results from this publication were expanded in 2012 when the group presented the outcomes after 50 transplants using lungs selected by EVLP [6] . Table 4 summarizes the most relevant outcome data for this experience.
Our group at the University of Maryland, in collaboration with five other lung transplant centers in the United States (Duke, Columbia, UPenn, University of Colorado, and Brigham's and Women), presented in 2013 the first multicenter and prospective clinical trial, the NOVEL Lung Trial, evaluating the safety of EVLP as a tool to screen the unused lung donor pool for good quality grafts [16 •• ] . This report included 31 lung transplants using lungs selected from the marginal donor pool using EVLP and compared to 31 lung transplants using standard criteria donors. No significant differences in outcomes were observed between the groups as seen in Table 4 .
To date, several centers around the world have used this technique to re-evaluate organs from the substandard lung donor pool looking to increase the number of transplants. Table 4 summarizes the published data with the use of EVLP as a method to re-assess or recondition organs from the unused lung donor pool.
Conclusions
Published reports from different centers using EVLP, show a growing body of evidence that favor its use to screen the suboptimal donor pool. Safety concerns regarding its ability to recognize good quality grafts from the high-risk donor pool are diminishing as data from large multicenter and prospective trials are published. As for the effects of reducing cold ischemic time by using a transportable EVLP system, the ongoing INSPIRE trial may bring some clarity once the data is published.
EVLP promises a new era in lung transplantation, providing investigators with a reliable platform to translate new therapies to improve graft quality.
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